Detection of QTc interval prolongation using jacket telemetry in conscious non-human primates: Comparison with implanted telemetry

British Journal of Pharmacology

Volumn 171, Issue 2, 2014, Pages 509-522

  Derakhchan, K ^a   Chui, R W ^a   Stevens, D ^a   Gu, W ^a   Vargas, H M ^a  

^a AMGEN INC   (United States)

Author keywords

cardiac repolarization; drug induced QT prolongation; electrocardiogram; implanted telemetry; Jacket telemetry; non human primates; QT interval; sotalol

Indexed keywords

SOTALOL;

ACCLIMATIZATION; ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART RATE; HEART RHYTHM; IMPLANTATION; INTERMETHOD COMPARISON; INVASIVE PROCEDURE; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; NON INVASIVE MEASUREMENT; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; QTC INTERVAL PROLONGATION; TELEMETRY; TOXICOKINETICS;

CARDIAC REPOLARIZATION; DRUG-INDUCED QT PROLONGATION; ELECTROCARDIOGRAM; IMPLANTED TELEMETRY; JACKET TELEMETRY; NON-HUMAN PRIMATES; QT INTERVAL; SOTALOL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ELECTRODES, IMPLANTED; HEART RATE; LONG QT SYNDROME; MACACA FASCICULARIS; MALE; SOTALOL; TELEMETRY;

EID: 84891277466     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12484     Document Type: Article

References (33)

1. Amouzadeh HR, Vargas HM, (2013). Safety pharmacology assessment of biopharmaceuticals. In:, Vogel HG, Maas J, Hock FJ, Mayer D, (eds). Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Springer-Verlag: Berlin, pp. 555-560.
2. Anonymous (2005). The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human biopharmaceuticals. ICH S7B. Available at: http://www.ich.org (accessed 22/11/2013).
3. Bass AS, Hanson LA, Jackson TA, (2009). Measuring the risk of Torsades de Pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures. J Pharmacol Toxicol Methods 60: 51-57.
4. Bazett HC, (1920). An analysis of the time-relations of electrocardiograms. Heart 7: 353-362.
5. Chui RW, Fosdick A, Conner R, Jiang J, Bruenner BA, Vargas HM, (2009). Assessment of two external telemetry systems (PhysioJacket and JET) in beagle dogs with telemetry implants. J Pharmacol Toxicol Methods 60: 58-68.
6. Chui RW, Derakhchan K, Vargas HM, (2011). Long-term assessment of non-human primate (NHP) ECG using jacketed external telemetry (JET): evaluation of heart rate and QTc interval variation over 6 months of observation. J Pharmacol Toxicol Methods 64: e45.
7. Derakhchan K, Cardinal R, Brunet S, Klug D, Pharand C, Kuś T, et al. (1998). Polymorphic ventricular tachycardias induced by d-sotalol and phenylephrine in canine preparations of atrioventricular block: initiation in the conduction system followed by spatially unstable re-entry. Cardiovasc Res 38: 617-630. (Pubitemid 28319871)
8. Derakhchan K, Chui RW, Vargas HM, (2011a). Utilization of jacketed external telemetry (JET) in conscious, non-human primates (NHP) over 1, 4, and 7 months: acclimation considerations. J Pharmacol Toxicol Methods 64: e45-e46.
9. Derakhchan K, Chui RW, Vargas HM, (2011b). Evaluation of cardiac conduction disturbances using jacketed external telemetry (JET) in conscious non-human primates (NHP). J Pharmacol Toxicol Methods 64: e46.
10. Gauvin DV, Tilley LP, Smith Jr FWK, Baird TJ, (2005). Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving cynomolgus monkey by remote radiotelemetry. J Pharmacol Toxicol Methods 53: 140-151.
11. Guth BD, (2007). Preclinical cardiovascular risk assessment in modern drug development. Toxicol Sci 97: 4-20. (Pubitemid 47072150)
12. Guth BD, Bass AS, Briscoe R, Chivers S, Markert M, Siegl PK, et al. (2009). Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. J Pharmacol Toxicol Methods 60: 107-116.
13. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K, (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 54: 116-129. (Pubitemid 44293425)
14. Institute for Laboratory Animal Research (2011). Guide for the Care and Use of Laboratory Animals, 8th edn. National Academies Press: Washington, DC.
15. Ishizaka T, Yoshimatsu Y, Ozawa M, Kimotsuki T, Takasaki W, Manabe S, et al. (2009). Evaluation of drug-induced QT prolongation in a halothane- anesthetized monkey model: effects of sotalol. J Pharmacol Toxicol Methods 59: 86-93.
16. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
17. Luft J, Bode G, (2002). Integration of safety pharmacology endpoints into toxicology studies. Fundam Clin Pharmacol 16: 91-103. (Pubitemid 34587794)
18. Lynch JJ, III, Wilson AW, Hernandez LE, Nelson RA, Marsh KC, Cox BF, et al. (2008). Dose-response effects of sotalol on cardiovascular function in conscious, freely moving cynomolgus monkeys. Br J Pharmacol 154: 1439-1445.
19. Macallum GE, Houston BJ, (1993). Characterization of cardiac alterations in nonsedated cynomolgus monkeys. Am J Vet Res 54: 327-332.
20. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
21. McMahon C, Mitchell AZ, Klein JL, Jenkins AC, Sarazan RD, (2010). Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. J Pharmacol Toxicol Methods 62: 127-135.
22. Prior H, McMahon N, Schofield J, Valentin JP, (2009). Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs. J Pharmacol Toxicol Methods 60: 167-173.
23. Redfern WS, Ewart LC, Lainée L, Pinches M, Robinson S, Valentin J-P, (2013). Functional assessments in repeat-dose toxicity studies: the art of the possible. Toxicol Res 2: 209-234.
24. Sarazan RD, Mittelstadt S, Guth B, Koerner J, Zhang J, Pettit S, (2011). Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities. Int J Toxicol 30: 272-286.
25. SAS (Statistical Analysis System) (1999). Version 8.02. SAS Institute Inc.: Cary, NC.
26. Sasaki H, Shimizu N, Suganami H, Yamamoto K, (2005). QT PRODACT: inter-facility variability in electrocardigraphic and hemodynamic parameters in conscious dogs and monkeys. J Pharmacol Sci 99: 513-522. (Pubitemid 44618151)
27. Soloviev MV, Hamlin RL, Barrett RM, Chengelis CP, Schaefer GJ, (2006). Different species require different correction factors for the QT interval. Cardiovasc Toxicol 6: 145-157. (Pubitemid 46277552)
28. Tattersall ML, Dymond M, Hammond T, Valentin JP, (2006). Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. J Pharmacol Toxicol Methods 53: 11-19. (Pubitemid 43052698)
29. Toyoshima S, Kanno A, Kitayama T, Sekiya K, Nakai K, Haruna M, et al. (2005). QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 99: 459-471. (Pubitemid 44618147)
30. Vargas HM, Derakhchan K, Chui RW, Stevens D, (2010). Evaluation of d,l-sotalol (SOT) using jacketed external telemetry (JET) in conscious non-human primates (NHP) over 4 weeks of evaluation. J Pharmacol Toxicol Methods 62: e24-e25.
31. Vargas HM, Amouzadeh HR, Engwall MJ, (2013). Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Expert Opin Drug Saf 12: 91-102.
32. Vogel AP, Jaax GP, Tezak-Reid TM, Baskin SI, Bartholomew JL, (1991). Ambulatory electrocardiography (Holter monitoring) in caged monkeys. Lab Anim 25: 16-20.
33. Wallis RM, (2010). Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br J Pharmacol 159: 115-121.